Answer
Mylotarg (gemtuzumab ozogamicin) has been associated with hepatotoxicity, including life-threatening and sometimes fatal hepatic failure and hepatic venoocclusive disease/sinusoidal obstruction syndrome (VOD/SOS).
Sources for this answer
- MYLOTARG 5mg powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 13Document updated
Sources checked